Clinical and Transcriptional Profiles Reveal the Treatment Effect of Adalimumab in Patients with Initial-Onset and Recurrent Vogt–Koyanagi–Harada Disease

References

• Moorthy RS, Inomata H, Rao NA. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol. 1995;39(4):265–292. doi:10.1016/S0039-6257(05)80105-5.
   PubMed Web of Science ®Google Scholar
• Du L, Kijlstra A, Yang P. Vogt-Koyanagi-Harada disease: novel insights into pathophysiology, diagnosis and treatment. Prog Retinal Eye Res. 2016;52:84–111. doi:10.1016/j.preteyeres.2016.02.002.
   PubMed Web of Science ®Google Scholar
• Wang K, Zheng C, Zhao G, Zhang M, Liu T, Li H, et al. High long-term drug-free remission rate for acute Vogt–Koyanagi–Harada disease with an appropriate immunosuppressive regimen. Retina. 2023;43(9):1496–1505. doi:10.1097/IAE.0000000000003837.
   PubMed Web of Science ®Google Scholar
• Oray M, Abu Samra K, Ebrahimiadib N, Meese H, Foster CS. Long-term side effects of glucocorticoids. Expert Opin Drug Saf. 2016;15(4):457–465. doi:10.1517/14740338.2016.1140743.
   PubMed Web of Science ®Google Scholar
• Fang W, Zhou H, Yang P, Huang X, Wang L, Kijlstra A. Longitudinal quantification of aqueous flare and cells in Vogt-Koyanagi-Harada disease. British J Ophthalmol. 2008;92(2):182–185. doi:10.1136/bjo.2007.128967.
   PubMed Web of Science ®Google Scholar
• Urzua CA, Herbort C Jr., Valenzuela RA, Abu El-Asrar AM, Arellanes-Garcia L, Schlaen A, et al. Initial-onset acute and chronic recurrent stages are two distinctive courses of Vogt-Koyanagi-Harada disease. J Ophthal Inflamm Infect. 2020;10(1):23. doi:10.1186/s12348-020-00214-2.
   PubMed Web of Science ®Google Scholar
• Ono T, Goto H, Sakai T, Nitta F, Mizuki N, Takase H, et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt–Koyanagi–Harada disease. Jpn J Ophthalmol. 2022;66(2):119–129. doi:10.1007/s10384-021-00878-w.
   PubMed Web of Science ®Google Scholar
• Liu S, Du L, Zhou Q, Zhang Q, Hu K, Qi J, et al. The choroidal vascularity index decreases and choroidal thickness increases in Vogt–Koyanagi–Harada disease patients during a recurrent anterior uveitis attack. Ocul Immunol Inflammation. 2018;26(8):1237–1243. doi:10.1080/09273948.2017.1343357.
   PubMed Web of Science ®Google Scholar
• Moll-Udina A, Miguel Escuder L, Hernanz I, Llorenç V, Fonollosa A, Cordero Coma M, et al. Adalimumab in elderly patients with non-infectious uveitis. Safety and efficacy. Ocul Immunol Inflammation. 2021;29(7–8):1591–1598. doi:10.1080/09273948.2020.1769139.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388(10050):1183–1192. doi:10.1016/S0140-6736(16)31339-3.
   PubMed Web of Science ®Google Scholar
• Shu J, Su G, Zhang J, Liu Z, Chang R, Wang Q, et al. Analyses of circRNA and mRNA profiles in Vogt–Koyanagi–Harada Disease. Front Immunol. 2021;12:738760. doi:10.3389/fimmu.2021.738760.
   PubMed Web of Science ®Google Scholar
• Yang S, Tao T, Li Z, Chen B, Huang Z, Liu X, et al. Systemic glucocorticoid-free therapy with adalimumab plus immunosuppressants versus conventional therapy in treatment-naïve Vogt-Koyanagi-Harada disease patients. Ann Transl Med. 2022;10(12):699. doi:10.21037/atm-22-2668.
   PubMed Web of Science ®Google Scholar
• Yang S, Tao T, Huang Z, Liu X, Li H, Xie L, et al. Adalimumab in Vogt-Koyanagi-Harada disease refractory to conventional therapy. Front Med. 2021;8:799427. doi:10.3389/fmed.2021.799427.
   Web of Science ®Google Scholar
• Nakai S, Takeuchi M, Usui Y, Namba K, Suzuki K, Harada Y, et al. Efficacy and safety of adalimumab for exacerbation or relapse of ocular inflammation in patients with vogt-koyanagi-harada disease: a multicenter study. Ocul Immunol Inflammation. 2022;1–9. doi:10.1080/09273948.2022.2092007.
   Web of Science ®Google Scholar
• Urzua CA, Velasquez V, Sabat P, Berger O, Ramirez S, Goecke A, et al. Earlier immunomodulatory treatment is associated with better visual outcomes in a subset of patients with Vogt-Koyanagi-Harada disease. Acta Ophthalmol. 2015;93(6):e475–480. doi:10.1111/aos.12648.
   PubMed Web of Science ®Google Scholar
• Köse B, Uzlu D, Erdöl H. Psoriasis and uveitis. Int Ophthalmol. 2022;42(7):2303–2310. doi:10.1007/s10792-022-02225-5.
   PubMed Web of Science ®Google Scholar
• O’Connor GR. Factors related to the initiation and recurrence of uveitis. XL Edward Jackson memorial lecture. Am J Ophthalmol. 1983;96(5):577–599. doi:10.1016/S0002-9394(14)73415-4.
   PubMed Web of Science ®Google Scholar
• Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. doi:10.1186/s13059-014-0550-8.
   PubMed Web of Science ®Google Scholar
• Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinf. 2013;14(1):7. doi:10.1186/1471-2105-14-7.
   PubMed Web of Science ®Google Scholar
• Wickham H. Ggplot2: Elegant Graphics for Data Analysis. NewYork: Springer-Verlag; 2016. https://org/ggplot2.tidyverse.org.
   Google Scholar
• Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101–1108. doi:10.1038/nprot.2008.73.
   PubMed Web of Science ®Google Scholar
• Herbort CP Jr., Tugal-Tutkun I, Abu-El-Asrar A, Gupta A, Takeuchi M, Fardeau C, et al. Precise, simplified diagnostic criteria and optimised management of initial-onset Vogt–Koyanagi–Harada disease: an updated review. Eye (Lond). 2022;36(1):29–43. doi:10.1038/s41433-021-01573-3.
   PubMed Web of Science ®Google Scholar
• Park HS, Park HY, Lee CS, Lee SC, Lee JH. Efficacy of combined systemic corticosteroid and early immunomodulatory therapy within three months of onset in Vogt–Koyanagi–Harada disease. Retina. 2022;42(12):2361–2367. doi:10.1097/IAE.0000000000003617.
   PubMed Web of Science ®Google Scholar
• Patocka J, Nepovimova E, Kuca K, Wu W. Cyclosporine A: chemistry and toxicity - a review. Curr Med Chem. 2021;28(20):3925–3934. doi:10.2174/1875533XMTEwpNDktz.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Al Rashed FA, AlBloushi AF, Tobaigy MF, Gikandi PW, Herbort CP, et al. Therapeutic window of opportunity in the acute uveitic phase of Vogt–Koyanagi–Harada disease: prevention of late autoimmune complications by early intervention. Acta Ophthalmol. 2023;101(2):e236–e245. doi:10.1111/aos.15254.
   PubMed Web of Science ®Google Scholar
• Urzua CA, Guerrero J, Gatica H, Velasquez V, Goecke A. Evaluation of the glucocorticoid receptor as a biomarker of treatment response in vogt-koyanagi-harada disease. Invest Ophthalmol Vis Sci. 2017;58(2):974–980. doi:10.1167/iovs.16-20783.
   PubMed Web of Science ®Google Scholar
• Karlidag R, Unal S, Evereklioglu C, Sipahi B, Er H, Yologlu S. Stressful life events, anxiety, depression and coping mechanisms in patients with Behçet’s disease. J Eur Acad Dermatol Venereol. 2003;17:670–675. doi:10.1046/j.1468-3083.2003.00760.x.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Berghmans N, Al-Obeidan SA, Gikandi PW, Opdenakker G, Van Damme J, et al. The CC chemokines CCL8, CCL13 and CCL20 are local inflammatory biomarkers of HLA-B27-associated uveitis. Acta Ophthalmol. 2019;97(1):e122–e128. doi:10.1111/aos.13835.
   PubMed Web of Science ®Google Scholar
• Gao C, Pu H, Zhou Q, Tao T, Liu H, Sun X, et al. Two reactive behaviors of chondrocytes in an IL-1β-induced inflammatory environment revealed by the single-cell RNA sequencing. Aging (Albany NY). 2021;13(8):11646–11664. doi:10.18632/aging.202857.
   PubMedGoogle Scholar
• Guo K, Li B, Yang F, Zhang M, Zhao G, Zhang X. Different MicroRNA profiles in peripheral blood mononuclear cells from patients with initial-onset and recurrent Vogt–Koyanagi–Harada Disease. Mol Biol Rep. 2022;49(12):11421–11431. doi:10.1007/s11033-022-07753-y.
   PubMed Web of Science ®Google Scholar
• Couto C, Schlaen A, Frick M, Khoury M, Lopez M, Hurtado E, et al. Adalimumab treatment in patients with Vogt–Koyanagi–Harada Disease. Ocul Immunol Inflammation. 2018;26(3):485–489. doi:10.1080/09273948.2016.1236969.
   PubMed Web of Science ®Google Scholar
• Hiyama T, Harada Y, Kiuchi Y. Clinical characteristics and efficacy of adalimumab and low-dose methotrexate combination therapy in patients with Vogt–Koyanagi–Harada Disease. Front Med. 2021;8:730215. doi:10.3389/fmed.2021.730215.
   Web of Science ®Google Scholar
• Shinagawa M, Namba K, Mizuuchi K, Iwata D, Hase K, Suzuki K, et al. The steroid-sparing effect of adalimumab in the treatment for the recurrent phase of Vogt–Koyanagi–Harada disease. Ocul Immunol Inflammation. 2023;31(3):501–505. doi:10.1080/09273948.2022.2037657.
   PubMed Web of Science ®Google Scholar
• Zhong Z, Dai L, Wu Q, Gao Y, Pu Y, Su G, et al. A randomized non-inferiority trial of therapeutic strategy with immunosuppressants versus biologics for Vogt-Koyanagi-Harada disease. Nat Commun. 2023;14(1):3768. doi:10.1038/s41467-023-39483-5.
   PubMed Web of Science ®Google Scholar
• Elhamaky TR. Long-term efficacy of dexamethasone intravitreal implant in the treatment of Vogt-Koyanagi-Harada disease relapsing posterior uveitis. Indian, J Ophthalmol. 2022;70(7):2465–2470. doi:10.4103/ijo.IJO_260_22.
   PubMed Web of Science ®Google Scholar
• Liu X, Jiang Q, Lv J, Yang S, Huang Z, Duan R, et al. Insights gained from single-cell analysis of immune cells in tofacitinib treatment of Vogt-Koyanagi-Harada disease. JCI Insight. 2022;7(23). doi:10.1172/jci.insight.162335.
   Web of Science ®Google Scholar
• El-Asrar AMA, Berghmans N, Al-Obeidan SA, Gikandi PW, Opdenakker G, Van Damme J, et al. Differential CXC and CX3C chemokine expression profiles in aqueous humor of patients with specific endogenous uveitic entities. Invest Ophthalmol Vis Sci. 2018;59(6):2222–2228. doi:10.1167/iovs.17-23225.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Dheyab A, Khatib D, Struyf S, Van Damme J, Opdenakker G. Efficacy of B cell depletion therapy with rituximab in refractory chronic recurrent uveitis associated with Vogt-Koyanagi-Harada disease. Ocul Immunol Inflammation. 2022;30:750–757. doi:10.1080/09273948.2020.1820531.
   PubMed Web of Science ®Google Scholar